Purest pick-and-shovel of injectables: elastomer closures + RTU components + self-injection devices. GLP-1 demand consumed high-value syringe/stopper capacity faster than suppliers can validate. Annex 1 RTU conversions additive.
Research snapshot · Not reviewed
WSTWest Pharmaceutical Services
Injectable packaging, containment, delivery
Open WST in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap25.84BSnapshot value
GLP-1 injectable dominance (each pen bundles glass + elastomer + device); Medicare GLP-1 Bridge (live July 1 2026 ~$50 copay); ~2031 patent cliff (biosimilars still need fill-finish); SmartDose 3.5ml divestiture to AbbVie mid-2026.
Oral GLP-1 bypassing sterile bottleneck (Lilly Foundayo launched April 2026); GLP-1 ~20% exposure as swing factor; capacity coming online 2026-2027 (finite tightness); Novo/Catalent in-housing.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · ins-$1.1M · 13F 17+/8- · short↑0.33
Snapshot · Not reviewed